Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oxford Diffraction is a leading developer of X-ray crystallography instrumentation and software, essential for structural biology and drug discovery. The company specializes in high-performance diffractometers and CCD detectors that allow researchers to determine the three-dimensional atomic structures of proteins and small molecules. Its CrysAlisPro software is widely regarded as an industry standard for data collection and processing in the crystallography community. Founded in 2001 as a joint venture, the company was acquired by Varian in 2008 and subsequently became part of Agilent Technologies. In 2015, the business was acquired by Rigaku, where it now operates under the Rigaku Oxford Diffraction brand.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oxford Diffraction.